From Prevention to Treatment: How Biological Rhythms Can Maintain Perinatal Mental Health
Innovations in Biological Rhythms in the Context of Mental Health: Effectiveness of New Technologies and Exposure to Different Lighting Patterns in Women During the Postpartum Period
Hospital de Clinicas de Porto Alegre
150 participants
Jan 4, 2024
INTERVENTIONAL
Conditions
Summary
Depression and anxiety are significant public health issues during pregnancy and the postnatal period, particularly affecting those in developing countries. Disruptions in biological rhythms, sleep problems, and low exposure to daylight are associated with a higher risk of these mental health issues. The perinatal period poses unique challenges to the temporal program, with evidence indicating that sleep disturbances significantly increase the risk of postnatal depression. A Randomised Clinical Trial (RCT) is being conducted to assess the effectiveness of Blue Light Therapy (BlueLT) in treating depressive and anxiety symptoms during the postpartum. The RCT will also investigate the alignment of rest-activity and internal body time as mediating factors. This study will focus on various chronobiological factors, including rest-activity rhythms, light exposure levels, temperature rhythms, sleep duration and phase, social jetlag, and BodyTime (assessed through a single blood sample). The goal is to recruit 50 women with postpartum depression, with 25 in the BlueLT intervention group and 25 in the ControlLT placebo group, alongside 100 healthy controls. The BlueLT device uses a short-wavelength LED lamp mainly composed by a wavelength peak on blue spectrum, while the ControlLT device has a dim long-wavelength LED. A Healthy Control group will also be included to account for changes unrelated to depression diagnosis or placebo/treatment effects. Exclusion criteria involve a history of major depressive or anxiety disorder, current psychotic disorder, night shift work, active suicidal thoughts, unstable medical conditions interfering with data collection, and newborns with severe health conditions. The study aims to evaluate the impact of BlueLT on postpartum depression and understand the role of chronobiological factors in the health/disease process.
Eligibility
Inclusion Criteria3
- weeks postpartum;
- Postnatal depression confirmed through Edinburgh Postnatal Depression Scale (EPDS) \> 10;
- Mini-International Neuropsychiatric Interview (M.I.N.I.) positive for current depressive episode.
Exclusion Criteria4
- Active suicidal ideation;
- Psychotic symptoms;
- Unstable general medical conditions that interfere with the acquisition of actigraphy;
- Newborn with severe health conditions (hospitalization, care in the neonatal ICU).
Interventions
The BlueLT device is equipped with a narrow band short wavelength Light Emitting Diode (LED) - wavelength peak(λp) of \~470 nm (blue).
The ControlLT (placebo) device is equipped with a dim long-wavelength enriched LED.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06246214